Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial
- 1 April 2003
- Vol. 61 (4) , 8-14
- https://doi.org/10.1016/s0090-4295(03)00115-8
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomyEuropean Urology Supplements, 2002
- Management of Erectile DysfunctionDisease Management and Health Outcomes, 2002
- VardenafilDrugs & Aging, 2002
- Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitorLife Sciences, 2001
- Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic studyWorld Journal of Urology, 2001
- Future considerations: advances in the surgical management of erectile dysfunctionInternational Journal Of Impotence Research, 2000
- Erectile DysfunctionNew England Journal of Medicine, 2000
- The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequencesBJU International, 1999
- Oral Sildenafil in the Treatment of Erectile DysfunctionNew England Journal of Medicine, 1998
- Treatment of Men with Erectile Dysfunction with Transurethral AlprostadilNew England Journal of Medicine, 1997